The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine by Balboa, Emilia et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






The Complexity of Colorectal Cancer Biology — Putting
Bricks on the Path to Personalized Medicine
Emilia Balboa, Angel Carracedo and
Francisco Barros
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57172
1. Introduction
Boveri's hypothesis about the genetic basis of cancer, a century ago, subsequently confirmed
by Loeb et al. in 1974, opened the gate for genetic studies that became essential for cancer
management. [1, 2]
Cancer is a disease that arises from altered cell due to multiple genetic and epigenetic altera‐
tions that confer them the properties of apoptosis evasion and growth advantage. These
properties represent a competitive advantage over normal cells, leading to the expansion and
colonization of other tissues by these cells, which cause patient´s death by interfering with the
normal function of its organs. [3]
Introduction of chemotherapy in cancer treatments has supposed an important improvement
in progression-free survival but, it is also associated to life threatening secondary effects, in
the worst scenario, and an important quality life reduction in the best one. Furthermore, due
to the difficulty to stratify patients in low and high risk, there are a substantial number of them
that will receive the therapy but will not experience any benefit from it. These consequences,
underline the importance of personalized treatment in cancer management. [4, 5]
The first chemotherapy treatments were based on a frequently observed characteristic of cancer
cells, this is, a high proliferation index. Their effectiveness rates vary among cancers, but all of
them are characterized by important secondary effects as consequence of their low specificity,
since these chemotherapeutics also affects normal cells.
The use of this traditional chemotherapy effectively shrinks tumor mass but, observation of
tumor metastases and recurrences led to the idea of the existence of cell populations unaffected
by the treatment, either because they are a type of cells with different characteristics from the
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cells that the drug was designed to, because they have undergone genetic changes that confer
them resistance or because the microenvironment protects them. Identification of the resist‐
ance cause is one of the cornerstones of cancer treatment and in this attempt, identification of
cells that have tumorigenic potential to sustain cancer is fundamental. [6]
Based on this, studies of tumor organization were performed. As indicated by Shackleton et
al, research on tumor organization intends to determine which cells have tumorigenic potential
to sustain cancer, this is, all cells in a cancer or only a specific population of them. There are
two principal models of tumor organization, not mutually exclusive, the clonal evolution
model [stochastic] and the stem cell model [hierarchical], that have been subjected to deep
examination owing to their implications in cancer management. [6]
The clonal evolution model was described by Nowell in 1976, and it is quite verified that it
seems to be ubiquitous in all cancers. It describes cancer development by the successive
acquisition of differential features in the derived cells giving rise to the formation of cell clones,
this is, group of cells with common features because they originate from the same progenitor
cell that can be a stem cell or not. Some of these features can be positive and provide a selective
advantage to these cells over the others, with the consequent establishment of these clones.
This model supports the idea that all cells in a tumor are important since the cancer can be
sustained due to the possible acquisition of resistance or advantage features in the derived
cells. On the other hand, this process is not random, tumors share similarities, but these
similarities will be modulated by the tumor environment turning each tumor into unique
entities. [3, 7]
To establish a model of tumor organization is fundamental since it should drastically change
treatment cancer approach. Identification of cells that drive tumor progression will allow us
to design target drugs against this cells instead of nonspecific drugs that treat all cancer cells,
even normal cells. Tumors that have a hierarchical organization from stem cells to more
differentiated cells are said to follow the stem cell model that have been recently proved in a
few cancers, among them, the colorectal cancer. [3, 6-13] Stem cells are a very specific type of
cells that possess differential capabilities such as being pluripotent, remain in a quiescent state,
have a long life as well as self-renewal capacity which allows them to perpetuate themselves
and repopulate different cells linages.
Nonetheless, both models are not incompatible, mutation causing clonal expansion may
happen in the stem cell compartment and manifests its effects on the progenitors cells or may
happen in the progenitors cells that can re-activate the auto-renewal machinery to generate
stem cells. [14] As long as the disease progresses, these changes can induce alterations in the
normal patterns of development of these cells, reducing their ability to differentiate and
increasing their auto-renewal capacity, causing the uncontrolled increase of undifferentiated
cells, as it happens in leukemia. [15] As Nowell denoted the observation of non-differentiation
of tumor cells is explained by focus the cell resources in increasing cell proliferation and
invasiveness. [3]
Both models describe a scenario of intratumor genetic heterogeneity that reproduces the tumor
tissue heterogeneity observed in patients, and also describes the heterogeneity observed in the
different stages of cancer as consequence of selection in different environments. [3, 7]
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Nonetheless, cells in this tissue are not independent units, there is a communication between
them and even collaboration has been proved in leukemogenic cells. [16] This communication
is performed through the extracellular matrix by different signals to which cells respond and
its behavior is modulated by these signals as them change over time. Hence, during cancer
development, cells in a tumor, experiment different genetic alterations selected by their fitness
which is determined by the tumor microenvironment and tissue characteristics where the
tumor is being developed. All these characteristics explain the observed intra-tumor hetero‐
geneity in cancer and the different subtypes identify in a specific type of cancer, which added
to the modification performed by the individual genetic background makes each cancer a
unique entity. [7]
To add more complexity to the system, not all the mutations within a tumor are important for
its progression or survival. Due to alterations in DNA repair systems, numerous mutations
are produced that do not provide any advantage nor disadvantage to cells at a given moment
but, its presence and proportion in the tumor mass will depend on if they are produced in
clones which have driver mutations, this is mutations that will lead tumor development and
response to the environment. Differentiate which mutations are drivers from passengers it is
another important and confounding factor for both, identification of tumor and pharmacoge‐
netic markers. [7, 17, 18]
Equally importantly is to determine the global effects that mutations cause, since understand‐
ing the aims of the tumor through the modulation of the pathways that performs will help us
to predict the compensatory mechanism that executes. [3] Knudson´s two hits hypothesis
postulates that more than one mutation is needed in cells to become malignant. [19, 20] The
fine regulation that tumor cells exert, and the importance of the molecular pathways implied
is exemplified by the °Just-right hypothesis° that postulates that the second mutation in the
adenomatous polyposis coli [APC] gene [which is a gene where germline mutations are found
to be associated to an hereditary form of colorectal cancer] produces in a tumor is dependent
on the type and localization of the germline mutation in a patient in order to maintain some
basal APC activity, which it is needed for cell functioning. [21]
Apart from all these convolutions, each tumor has an inherent progression; there is a pattern
of genetic alterations typical of each tumor, whose establishment is a priority when designing
cancer treatments. The goal is to increase drug efficiency along with its specificity in order to
diminish the secondary effects. In this road, there have been two important events that have
helped us to achieve this ultimate goal.
Firstly, advances in knowledge of genetics have allowed us to discover the hereditary compo‐
nent of cancer as well as the steps that follow in cancer development, the more important
pathways trigger in them and have pointed out the key deregulated molecules against to specific
drugs can be designed. The studies realized to determine the cancer characteristics have also
contributed to the discovery of specific and differential patterns of each cancer. [22-25]
Secondly, drug development research has focused their efforts in the development of target
drugs that act specifically on those molecules in order to avoid the important secondary effects
of classical chemotherapy.
The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine
http://dx.doi.org/10.5772/57172
435
Molecular specific drugs, like tyrosine kinase inhibitors or antibody-based therapies are the
next-generation cancer treatment. [4] As result of this molecular specificity, effectiveness of
these selective treatments is more dependent on the biology of the target cell. Consequently,
the pace of the improvements in cancer treatments is highly dependent on the knowledge of
cancer cells biology.
But, as stated above, cancer cells are not islands, its behavior is modulated by the signals that
its surroundings emit, as well as its surroundings control the quantity of nutrients, oxygen and
chemicals that reach the tumor. Therefore, treatment efficiency is influenced by drug phar‐
macokinetics, that is dependent of the biology of the normal cells, as well as the secondary
effects are determined by drug pharmacodynamics, that is subject to drug specificity and the
inherited sensibility of normal cells to chemotherapeutic agents determined by different
mechanisms, for example, detoxifying mechanisms. [3] Subsequently, when trying to person‐
alize treatments it is important to identify both, the genetic of the tumor and the genetic of
normal cells. This is one of the causes that explain the variability in response to chemotherapy
observed in patients with similar tumor characteristics. [4]
Despite the efforts realized, the only pharmacogenetics markers used today in clinic are KRAS
and BRAF mutations. Some of the causes of this delay in markers discovery are then. No
intention of this chapter is to provide a deep review of the different subtypes but offer an
outline of the principal characteristics of the diverse subtypes according to the literature, in
order to expose the cause of the delay in markers discovery that was previously mentioned,
and reflect that problems in pharmacogenetic studies obtained are due, in part, to the high
heterogeneity in colorectal cancer which makes difficult to establish clearly differentiated
groups of study and at the same time, to reflect that intense research has a positive point of
view, since important advances in tumor characterization and target molecules discovery have
also been done.
2. Colorectal cancer biology — Heterogeneity of colorectal cancer
Colon tissue is organized in a repetition of structural subunits called crypts. Cells in each crypt
have an ordered configuration, being the stem cells at the base of the crypt and the subsequent
differentiated cells upwards along the crypt. The main conductor in the colonic cell differen‐
tiation is the Wnt/β-catenin signaling pathway. [26] β-Catenin is a transcriptional co-activator
of genes implicated in cell growth and differentiation. Activation of the Wnt pathway disrupts
the cytoplasmatic complex that marks β-catenin for degradation allowing it to enter the
nucleus were exerts its activity. [27-29] APC protein forms part of the degradation complex.
Concordant to their function in the differentiation and growing pattern, there is an inverse
gradient of APC/β-catenin expression along the crypt axle, being APC mostly expressed in the
upper part of the crypt and β-catenin in the lower part on the crypt. [30]
Colorectal cancer is a highly heterogeneous malignancy caused by genetic and epigenetic
alterations in the stem cells of the crypt of the bowel which give rise to precancerous lesion,
aberrant crypt foci, that overgrow usually forming polyps that after a successful accumulation
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of genomic alterations become tumor cells. [11-13, 31, 32] It can arise in a sporadic form or it
can have a hereditary component.
Identification of the cause that predisposes to cancer in the hereditary syndromes have given
us clues, due to the similarities of the mechanisms identified, to understand what happen in
the sporadic tumors, that involves the majority of the colorectal cancer cases. Germline
mutations in known oncogenes or DNA repair genes have been identify as causative of a
predisposition to endure colorectal cancer but the origin of the sporadic form is still unclear
and it is attributed to genetic alterations caused by the environmental as chemical carcinogens,
age related factors which increase DNA errors rate and nutritious factors. All these conditions
will probably determine the activated cancer mechanism depending on which factor has
triggered the cancer. But, environment is also an important factor that modulates colorectal
cancer appearance in patients with a hereditary component since germline mutations cause a
predisposition to cancer, but another mutation is needed in the cells for them to become
malignant, as it is postulated in Knudson´s two hits hypothesis. [19, 20]
In recent times it has become evident the need of establish subtypes in colorectal cancer due
to the differential characteristics of the proximal and distal segments of the colon as well as
diverse features, at both histological and molecular level, observed in colorectal cancer.
Proximal and distal colon, proceed from a different embryological origin, midgut and hindgut
respectively. Besides the embryological origin, its distinctions span from innervation and
blood supply to functional differences and differential gene expression. [33, 34]
At histological level, most the polyps are adenomatous [95%], but only a small percentage of
them progress to cancer and not all the colorectal cancer cases are presented with polyps.
[35-37] Actually, prevalence of each type of polyp is only rough since it is population depend‐
ent, due to its genetic background and environmental dependence apart from the expertise of
the pathologist to identify the polyp, which sometimes is difficult. [37, 38] Histological features
of the tumors are associated to the underlying molecular pathway. So far, two main types of
carcinoma have been identified, traditional and serrated carcinomas, that have several
subtypes and whose development is driven by three main molecular mechanisms, chromo‐
somal instability (CIN), microsatellite instability (MSI) and CpG island methylator phenotype
(CIMP). Combinations of these mechanism and some additional genetic and epigenetics
changes according to the tumor environment give raise to the large varieties of histological
forms observed. [38]
On molecular basis, colorectal cancer development is mainly, but not exclusively, driven by
the deregulation of one of these mechanisms (CIN, MSI or CIMP), CIN being the most
prevalent. [23, 39-44] But it not clear if these mechanisms are the cause or the major alterations
trigger in cancer. [2]
The predominance, of one of these mechanisms over the others, since they are not mutually
exclusive, provides the tumor their differential features, which includes morphological
characteristics, cancer prognosis and treatment efficiency. This heterogeneity observed in
colorectal cancer is due to the diverse scenarios in which colorectal cancer develops so,
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characterization of the colorectal cancer in different subtypes, according to its distinctive
signatures, will help us to stratify cancer progression risk and personalize treatments. [45-47]
But these subtypes are not mutually exclusive, the intra-heterogeneity observed in a patient´s
polyps reflects the heterogeneity of the molecular pathways and mechanisms that can be
implicated. [37]
Despite this overlap, predominant characteristics can be distinguished into the subtypes and
even alterations that are, in principal, mutually exclusive have been identified, that reflect the
unique signature of each tumor. [48, 49]
2.1. Molecular mechanism
2.1.1. Chromosomal instability mechanism – CIN
Chromosomal instability mechanism (CIN) is detected in the 65-70% of the colorectal cancers.
It is defined by the identification of changes at chromosomal level in tumor cells that cause
gene dose variations. [2] This mechanism is associated to the major hereditary syndrome, the
polyposis adenomatous familiar (FAP) as well as its attenuated variant (AFAP), that accounts
for 1% of the colorectal cases and it is the most frequently detected in the sporadic form [38,
50-52]. Less commonly, CIN is categorized in subtypes as CIN-high and low. [47, 52, 62]
The molecular steps that describe this mechanism were proposed by Fear and Vogelstein in
the °adenoma-carcinoma sequence°, where mutations in the APC gene (chr.5q) is the first step
identified in a sequence of genetic alterations on oncogenes and tumor suppressor genes that
leads to its keys characteristics, the aneuploidy and loss of heterozigosity. [22, 52-54]
Germline mutations in the APC gene are associated with these hereditary syndromes, as well
as mutations in this gene are detected in the 72%-85 of sporadic colorectal cancer cases and
hypermethylation of its promoter in the 18%. According to the importance of the Wnt pathway
in the colorectal cancer, in half of the patients where genetic alterations in APC are not detected,
gain of function mutations in the β-catenin gene have been found that account for 10% of
colorectal cases. [52, 55-57]
Besides its function in the repression complex of the β-catenin, APC has numerous functions,
among which highlights its implication in chromosomal segregation and, according to its
parallel increasing expression with cell differentiation, plays a role in different features of cell
differentiation. [52, 55, 56]
Mutations in APC are followed by genetic alterations with a different frequency, in KRAS,
DCC, SMAD4 and p53 that are detected in the progression of a tumor from adenoma to
carcinoma. [22, 58] All these genes are key points of regulation of important pathways that
control cell behavior thus, KRAS [chr.12p] is member of the Ras and PI3K pathway, which are
usually dysregulated in cancer and is implicated in cell proliferation, differentiation, survival,
metabolism and apoptosis. Its activation triggers both pathways. [58, 59]
SMAD4 belongs to the transforming growth factor β pathway signaling which is a tumor
suppressor pathway. Its inactivation is related to tumor progression and invasion, being
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associated to the transition from adenoma to carcinoma. This pathway has also a function on
the microenvironment regulation of cell by autocrine and paracrine factors. [58, 60]
Because of its important and numerous functions in cells, like cell cycle regulation or mainte‐
nance of genomic integrity, p53 (chr.17p) is called the guardian of the genome. Being one of
the most frequently mutated genes in cancer, its inactivation is associated to metastasis. [58, 61]
Nonetheless, the establishment of the adenoma-carcinoma sequence does not implied that all
mutations described are needed for the progression of cancer nor the uniques but the more
frequently ones detected, with different prevalence across the stages. [22]
2.1.2. Microsatellite instability (MSI)
Microsatellite instability (MSI) is defined by the detection of alterations in the length of short
repeated sequences known as microsatellite, which is indicative of defects in the DNA
mismatch repair system (MMR). These alterations influence expression of the affected genes.
[63] The genes that have been found associated to this altered mechanism are MLH1, PMS2,
PMS1 and MSH6. This mechanism is detected in 15-20% of colorectal cancers in both sporadic
and hereditary tumors. It is the main feature of another hereditary syndrome, Lynch syndrome
that accounts for 2-3% of colorectal cases. [38, 64] The number of altered microsatellites, is also
important, defining two subtypes as this number is high, MSI-H, or low, MSI-L. [65]
Mutations in MUTYH are associated to another hereditary syndrome, rarely found in sporadic
cases, called adenomatous polyposis associated to Mutyh (MAP). This protein belongs to the
DNA base-excision repair system, which is important in DNA oxidative damage repair that
causes guanosine (G) to thymidine (T) transversions. [66] Molecular mechanisms are not yet
totally clarified and polyps from MAP have some of the features but not all of both, CIN and
MSI mechanism. [67, 68]
2.1.3. Methylator Phenotype (CIMP)
CpG island methylator phenotype (CIMP) is defined by the detection of high degree of
methylation. [69] Hypermethylation of the promoter region causes silencing expression of
affected genes. It is generally age-related and it is related to cell response to inflammation. [65]
This mechanism is frequent in sporadic tumor and has also been detected associated to
hereditary mechanisms with a non-Darwinian patter of inheritance. [58, 70-75] There are two
panels of genes studied to identify the CIMP state, which define two subtypes, CIMP-high and
CIMP-low. CIMP-H is associated to neoplastic methylation meanwhile CIMP-L are age related.
2.2. Molecular pathways
2.2.1. Traditional pathway (Chromosomal instability mechanism – CIN)
The traditional pathway of colorectal cancer is the most prevalent, 60% of CCR arise by this
pathway. [76] Histologically, tumors that follow the traditional pathway are tubular polyps
that can be subdivided into tubular, tubulovillous and villous, being the former the most
The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine
http://dx.doi.org/10.5772/57172
439
prevalent. Colorectal cancer from FAP and AFAP patients, are the canonical tumors develop
by these pathway. This type of adenomas affects the epithelial layer and are originated from
dysplastic aberrant crypt foci. [77]
CIN is the most prevalent molecular mechanism in the traditional pathway of colorectal cancer,
which is also characterized for being microsatellite stable (MSS) and CIMP-. Tumors driven
by this mechanism are more frequently detected in distal localization and have a worse
prognosis than MSI tumors. They recently have showed the use of CIN as useful marker for
predicting survival, being patients that harbors CIN high tumors associated with a poor
survival. [62]
Adenoma – carcinoma sequence also lies beneath Lynch syndrome polyps but develops at a
faster tempo. [78, 79] Lynch syndrome polyps are more frequently associated to the proximal
colon, and even though it can be tubular, are more frequently associated with a mucinous or
signet ring histology and villous structures. These polyps show a high grade dysplasia, poorly
differentiated cells and Crohn’s-like infiltration of lymphocytes which has been found
associated to an increased survival. These polyps have higher risk of cancer but are less
invasive, have a better prognosis and a different response to chemotherapeutics. Less fre‐
quently these polyps have KRAS or p53 mutations. [64, 65, 78-80]
Although, presence of this mechanism in tumors has been reported to be inversely related to
CIMP, either CIMP-L or CIMP-H, [81, 82] there is a subgroup of CIN/MSS tumors characterized
by the presence of BRAF mutation that seems to be correlated with CIMP and poor survival.
[83] BRAF is implicated in MERK-ERK activation pathway by its recruitment by KRAS.
Confirming previous reports of KRAS and BRAF mutations as mutually exclusive, these
tumors are wild type KRAS. [84]
2.2.2. Alternative pathway (KRAS)
The alternative pathway is still not very well characterized. Some studies indicate the presence
of KRAS as its hallmark. [85] Histologically, the presence of KRAS, p53 mutation and recently
GNAS, has been associated to villous histology and a high grade dysplasia [86-88] and the
presence of CIMP+ to tubule villous size, right side localization and amount of villous, [89,
90] as well as to a differential pattern of the Wnt pathway genes. [91] Villous polyps are also
characterized for being microsatellite stable [MSS] and CIMP-L.
2.2.3. Serrated pathway CpG Island [methylator phenotype (CIMP)
The serrated pathway underlines the 20-35% of colorectal cancer cases. [37, 76] Histologically,
it is characterized by hyperplastic polyps, sessile serrated polyps or traditional serrated
adenomas, originated from non-dysplastic aberrant crypt foci that can either be mucinous or
not mucinous. [77, 85, 92] This type of tumor is mostly localized in the proximal colon and has
bad prognosis. [37]
Serrated polyps can be hyperplastic (HP) (20-30%), sessile serrated adenomas (SSA) (2-9%)
and traditional serrated adenomas (TSA) (0.3%) that are subsequently divided into subtypes.
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HP can distinguish polyps of microvesicular type (MVHP), Goblet cell–rich type (GCHP) or
Mucin poor type (MPHP), according to their content in mucin. SSA can be with/without
cytological dysplasia as well as TSA can be with/without conventional dysplasia. [37, 76]
The molecular characteristic of the majority of serrated polyps is the BRAF mutation and CIMP
+ mechanism. [93]
The CpG island methylator phenotype (CIMP) is detected in 15%-40% of the colorectal tu‐
mors. [94, 95] This kind of tumor is mostly related to ageing and environmental factors. One of
these genes identified as susceptible of hypermethylation is MLH1, which belongs to the DNA
mismatch repair system (MMR), being the causal mechanism of MSI in the serrated pathway.
[37, 65, 69]
The sequential steps described in this pathway from normal mucosa to carcinoma goes from
the presence of BRAF mutation in microvesicular hyperplastic polyps and posterior acquisi‐
tion of CIMP phenotype in sessile serrated polyps to a co-occurrence of both genetics alteration
leading to sessile serrated polyps. The acquisition of MLH1 promoter methylation is related
to the carcinoma stage. [76]
Goblet cell-rich hyperplastic polyps (GCHP) and traditional serrated adenomas (TSA) are
associated to KRAS mutations and while it has not been demonstrated a progression of GCHP
to carcinoma, it was proved in TSA. It has also been suggested MSI-L after MGMT methylation
or partial MLH1 methylation. [76]
Tumors associated to MUTYH can be since hyperplastic and sessile serrated polyps to no
polyps at CRC presentation. A higher association of KRAS mutations (70%) has been found in
MAP tumors that follow the serrated pathway compared to sporadic (17%), as well as an
increased on G:C to T:A transversions (94% vs. 29%). The findings of mutations on APC in
adenomas indicate two pathways of development of MAP tumors. [67, 96]
These data seem to confirm that are, at least, as many cancers as patients.
3. State of the art of pharmacogenetics
Personalized medicine is based on the clinical use of molecular biomarkers. A biomarker is
any specific physical trait or measurable biological change in the organism related to disease
or health conditions, being a very broad concept that includes many different measurements
of a biologic status.
Besides being diagnostic [used for the establishment of a particular disease present in the
patient sample [97]] or prognostic [used for the establishment of an association with clinical
outcomes, such as overall survival or recurrence-free survival independently of the treatment
[98] biomarkers can be predictive, by the assessment of the likely benefit of a specific treatment
to a specific patient, [99] or pharmacodynamic, by the measurement of the drug effect in a
disease [100].
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The term, Pharmacogenetics, was first used by Vogel in 1959 as the science about the effects
of heritability on drug response [101]. According to the definitions approved by the US Food
and Drug Administration (FDA), pharmacogenetics is ‘the study of variations in DNA
sequence as related to drug response’ [102] while the more comprehensive term Pharmaco‐
genomics is defined as ‘the study of variations of DNA and RNA characteristics as related to
drug response’ [103]. Sometimes used indistinctly, Pharmacogenomics is related to the study
of whole genome, the gene transcripts and population variability, with the aim of predicting
the right treatment in individual patients and designing new drugs.
In last years work in the field has grown almost exponentially [104], at the same pace as the
expectations about the increasing of clinical benefit and reduction of the risk of adverse drug
reactions (ADR), at least in outliers, i.e. people whose drug responses are not “average” [105].
Nonetheless, adoption of validated pharmacogenetic markers into routine clinical practice has
been slow, mainly in the oncological field. Pharmacogenetics has mainly focused on the
association between monogenic polymorphisms and in variations in drug metabolism. [102]
But, limitations exist on the role of pharmacogenetics in cancer therapy, mainly because of the
non-concordance at genetic level between germinal and somatic line of patients [106]. Herit‐
ability can be used to assess toxicity, but there are major concerns in their use to assess
effectivity.
Today, more than a 100 drugs have pharmacogenomic biomarkers in drug labels approved by
the U.S. Food and Drug Administration (FDA), being 35 oncology drugs [107]. In the opposite
sense, the European Medicines Agency (EMA) has been more conservative in the implemen‐
tation of pharmacogenetic markers in drug labels.
In the oncology field, hematology has been the more rewarding, due in part to the lack of some
of the architectural barriers found in solid tumors. As result of the pharmacogenetic manage‐
ment, survival rates of some leukemias have improved drastically. Albeit the efforts realized
to infer drug efficiency from germline markers, the only ones that have been consistently
replicated across the studies for efficiency, are tumor markers, leaving germline markers for
the identification of patients with toxicity risk and posterior evaluation of risk/benefit of the
drug.
3.1. Colorectal cancer treatment efficiency
In colorectal cancer, 75% of patients with stage I to III can be treated with surgery alone or in
combination with chemotherapy, with a 5-year survival rate of 93.2%, 82.5%, and 59.5%,
respectively, in contrast with only 8.1% survival rate of patients harbouring stage IV disease. [108]
For patients management, the probability of distant metastasis and response to chemotherapy,
are the most important clinical variables. With or without surgery, adjuvant chemotherapy is
routinely employed to treat those colorectal cancer patients at high risk of developing recur‐
rence or, those who already have metastatic disease at the time of diagnosis (up to 20 %).
The initial standard treatment with 5-fluorouracil (5-FU), with a median overall survival of 12
months or less and an overall response rate of 10%, has evolved to combinations with oxali‐
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platin or irinotecan that have dramatically improved survival. [109-111]. The preoperative
application of radiotherapy with infusional 5-FU have significantly decreased, the rate of local
recurrence [112-114]. In advanced colorectal cancer fluoropyrimidine chemotherapies are
basics for treatment in combination with oxaliplatin or irinotecan [115]. The integration of
biological agents with conventional cytotoxic drugs has expanded the treatment of metastatic
disease, resulting in an increased response rate and survival and achieving downstaging for
surgical resection and potential cure. The currently approved and widely used targeted
treatments are the monoclonal antibodies bevacizumab that recognizes the vasculature
endothelial growth factor (VEGF) and cetuximab and panitumumab, targeting the epidermal
growth factor receptor [EGFR]. These combinations reach response rates of up to 50% with a
median time of progression free survival of 10–12 months for patients with advanced CRC.
Biomarker development is now essential to aid selection of patients likely to respond to
therapy, rationalizing treatments and improving outcomes. But the different approaches used
in order to establish biomarkers of the response to treatments in patients with CRC are not
lacking in controversial. Even though numerous biomarkers have been postulated to be used
as pharmacogenetic markers, only a few of them are actually being used to manage cancer
treatment [116].
3.2. Biomarkers of 5-FU response
Thymidylate synthase (TS) is the primary intracellular target of 5-FU. 5-FU acts by preventing
the methylation of the deoxyuridine monophosphate to deoxythymidine monophosphate by
forming a stable complex, 5-FU–TYMS, causing a thymine deficiency. [117] In CRC, the
overexpression of TS has been associated with 5-FU resistance. [118] Several studies analysed
genetic polymorphisms as potential predictive factors to 5-FU response [119] but the associa‐
tion between TS expression or TS polymorphisms and response after 5-FU adjuvant treatment
is still largely unclear. Thus, although most studies report a TS expression decrease with a
better response, [120] there are studies that contradict this association, regarding both the
genotype and level of expression, and that link genotypes of high expression of TS with a better
response [121] and even a lack of association. [116, 122] Among the several factors that can
explain the variability of results, a relevant role might be played by the use of germline genetic
data despite the target of 5-FU is the tumor cell. In fact, the TS genotypes from germline and
tumor cells from a single patient can differ widely in rectal cancer, distorting the influence of
TS on the response to 5-FU. [116]
Although MSI CRCs have a prognostic advantage, [123] mainly due to the minor metastatic
potential of MSI CRCs, [124] the predictive value of MSI is still controversial. [125-127] MSI is
a strong and well validated prognostic marker to be used in the decision making process in an
appropriate clinical setting, for example in stage II, the favourable outcome of patients with
MSI CRC suggests that adjuvant chemotherapy could be avoided. [128]
Loss of heterozygosity (LOH) or allelic imbalance (AI) is common in chromosomal instability
(CIN) CRC. LOH of chromosome 18q leads to the loss of the tumor suppressor gene Deleted
in Colon Cancer (DCC) and had been associated with a poor prognosis of stage II and III CRC
patients in several studies [129], but these data were not confirmed. [130] In addition, their role
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as predictor of outcome in CCR patients following 5-FU based adjuvant therapy, is contro‐
versial too.
Near 30–50% of colorectal tumors harbour mutations in the KRAS oncogene, 90% of the
mutations occurring either in codon 12 or 13. [131] However, there is no consensus about the
role of KRAS as a prognostic marker [132] and KRAS mutation can hardly be expected to be
a predictive marker of response to standard chemotherapy. [132, 133]
Global hypomethylation and hypermethylation of tumor, characterize epigenomic instability.
Due to this context of genomic instability is difficult to know how the hypermethylated
phenotype “CpG island methylator phenotype” (CIMP) affect survival rate. Despite initial
results, [134] CIMP positivity in CRC seems not to be a significant independent predictor of
survival benefit from 5-FU chemotherapy. [135]
3.3. Biomarkers of platinum response
Glutathione, a ubiquitous tripeptide thiol, is a vital antioxidant and has a protective role against
a range of toxins including metal compounds such as cisplatin. Glutathione S-transferase P1
(GSTP1) acts directly in the detoxification of platinum compounds so it is an important factor
related to resistance to platinum [136]. However, and despite initial studies [137] reporting the
association between GSTP1 Ile105Val and oxaliplatin efficacy and toxicity, results of subse‐
quent studies were inconclusive. [138, 139]
High levels of excision repair cross-complementing 1 (ERCC1), an endonuclease of the
nucleotide excision repair (NER) system, are associated with an increased platinum resistance.
[140, 141] The x-ray repair cross complementing group 1 (XRCC1), a member of the base
excision repair (BER) pathway, links to other proteins related to the BER pathways and repair
specific base damage, caused by oxaliplatin. [142] XRCC1 polymorphisms increase the risk of
oxaliplatin resistance, via inadequate repair or increased damage tolerance. [143] XPD
(ERCC2) has an important role in DNA repair by removing bulky DNA adducts produced by
environmental toxins and xenobiotics. The XPD Lys751Gln polymorphism has been associated
to clinical outcome following platinum-based chemotherapy. [136, 139, 144]
3.4. Biomarkers of monoclonal antibodies response
There is a wide consensus on the predictive value of KRAS mutations in response to treatment
with anti-EGFR drugs. Interestingly, a single first study, in barely 30 patients with metastatic
CRC treated with cetuximab, demonstrated the relation between KRAS mutation and non-
response: KRAS mutations were found in 68% of non-responding patients but in none of the
responders. [145] [145]. The fact is that KRAS is downstream in the EGFR signalling pathway
and that pathway is activated by KRAS mutations irrespective of the receptor status, overrid‐
ing the efficacy of anti-EGFR therapy. The Food and Drug Administration (FDA) approved,
in a record time, label changes to cetuximab and panitumumab to advise against their use in
patients with KRAS positive metastatic CCR [146, 147]
BRAF mutations also affects the EGFR signalling pathway and are found in CRC at lower
frequency than KRAS (≤10%), in fact BRAF and KRAS mutations are mutually exclusive events
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in tumors. [148] The most frequent BRAF mutation (V600E) represents 50% of BRAF mutations
in CCR, being more common in MSI CRC, than in microsatellite stable tumors. [128] BRAF
mutation is involved in MEK-ERK pathway activation and CRC carcinogenesis. BRAF V600E
is also associated with the CIMP phenotype, 70% of CIMP CRC can harbour BRAF mutations.
[93] BRAF mutations have been associated with poor prognosis in patients with stage IV CRC.
In agreement with the role of BRAF mutations in enhancing stimulation of downstream MEK-
ERK signalling, in patients with metastatic CRC, BRAF mutations are predictive of non-
response to EGFR-targeted agents. [149]
3.5. Biomarkers of toxicity
As stated previously, more than a 100 drugs have pharmacogenomic biomarkers in drug labels
approved by the FDA. It is paradoxical that, while germline genetical markers should be better
for the identification of patients with toxicity risk, the efforts in pharmacogenetic studies were
realized to infer drug efficiency. Only six of the FDA approved oncology biomarkers are
associated with toxicity. DPYD*2A for capecitabine and UGT1A1*28 irinotecan are the
biomarker associated to CRC chemotherapy. [107]
With this data, the problem related to discovering biomarkers of ADRs is clear. Most studied
biomarkers related to ADRs are reflected in Table 1, but they are not extensively used in clinical
practice.
Gene Treatment Toxicity Review
DPYD fluoropyrimidine myelotoxicity
Amstutz U et al. Pharmacogenomics. 2011, 12 [9]:1321-36
FDA: XELODA® [capecitabine] Label [http://
www.accessdata.fda.gov/drugsatfda_docs/label/
2011/020896s026lbl.pdf]
UGT1A1 irinotecan Myelotoxicity severediarrhea
Marques SC, Hum Genomics. 2010, 4 [4]:238-49
FDA Camptosar® Label [http://www.accessdata.fda.gov/
drugsatfda_docs/label/2006/020571s030lbl.pdf]
EGFR EGFR inhibitors Skin rash Galvani E, Future Oncol. 2012, 8 [8]: 1015-29
VEGF VEGF inhibitors hypertension Schneider BP, J. Clin. Oncol. 2008,26 [28]: 4672–4678














Cortejoso L, López-Fernández LA. Pharmacogenomics.
2012, 12 [10]:1173-1191
Table 1. Association of genes to toxicity in colorectal treatments.
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3.6. Biomarkers used in clinical practice
In conclusion, currently the UICC/AJCC Tumor Node Metastasis (TNM) stage system remains
the only valid prognostic marker for predicting the outcome of CRC patients. [150-155] Besides
different histomorphological, immunohistochemical and molecular biomarkers have been
proposed [156, 157] to improve stratification of CRC patients into prognostic subgroups. But,
if no additional prognostic and predictive factors were included in the pre- and postoperative
management of non-metastatic CRC until now, for metastatic CRC patients gene mutations
are arising as predictive biomarker, mainly the KRAS mutational status, with the implemen‐
tation of anti-EGFR therapy.
4. Establishment issue of genotype-phenotype correlations in cancer
In the last years, numerous candidate prognostic and predictive markers have been reported
in hundreds of studies and failed to demonstrate clinical utility. It is difficult to review, even
monthly, all described molecular markers of prognosis. Clearly a validation is necessary to
establish an association between any of these markers with prognosis or with the response to
therapy but the validation itself is not an explanation of why so many potential markers fail
to be validated. Inconsistencies can arise between initial reports and subsequent studies
because differences in assays, study design, genetic substructure of human populations,
statistical power or methodologies. But the establishment of clear genotype-phenotypes
correlations, mostly in solid tumors, is still a wide and difficult field of study due to several
reasons:
4.1. Architecture of solid tumor
Hematologic cancers treatments have turned them, in some cases, in chronic diseases with the
appropriate treatment. Even though they share a common problem with solid tumor, this is,
localization and properties of the cancer stem cells, majority of leukemia cells are located in
the bloodstream so once drugs reach the bloodstream do not have additional barriers to
trespass but the cellular membrane. This more easily access by the drug allows reduce cancer
cells load.
But in solid tumors, drugs have to overcome several barriers to access the cells. To get access
to tumor drugs first have to extravasate and diffuse across the extracellular matrix to reach all
the cells in a tumor, included not well irrigated zones where transportation into the cells is
even more difficult due to the extracellular acidic pH. [158, 159]
Tumor mass is a not equally organized mass of cells with an equally distributed blood capillary
network that supplies all cells in a tumor but a disorganized mass of different cells with
unequally blood supply subject to a different interstitial fluid pressure that produce differential
gradient of molecules distribution, among them, drugs. Thus, obstruction of an adequate
intratumoral drug delivery in one the cause is one of the causes for cancer recurrence. [158, 159]
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Indeed, modification of tumor microenvironment is one of the novel mechanisms to overcome
drug resistance. [160, 161]
4.2. Tumor microenvironment
It is already established that tumor microenvironment has an important role in tumor behavior
as well as physical impediment of drug delivery but its function in promoting cancer devel‐
opment and drug resistance by segregating molecules by stromal cells have been recently
proved. [161-164]
In colorectal cancer, presence of tumor-infiltrating lymphocytes, as part of the immune system
response, has been associated positively to both survival and chemotherapy response. [165, 166]
Straussman et al. showed that resistance to RAF inhibitors are not only due to gene activated
mutations but mediated by the segregation of hepatocyte growth factor (HGF) by the stromal
cells. Their work confirmed the microenvironment as a frequent cause of chemotherapy
resistance, principally to targeted drugs [164].
4.3. Intertumor heterogeneity
Similar to other natural ecosystems, tumor growth and development is dependent on the niche
conditions. In the case of a tumor, these conditions are primarily determined by the genetic
background and physiological state of the patient and lately, determined by the genetic of the
tumor itself. And as it happens in all ecosystems, tumor is not in a static state, as the environ‐
ment changes, the tumor will be adapted to the changed conditions. The different conditions
in which a tumor will be developed [a unique mixture of genomic and epigenomic features]
determine its specific features, which are improbable to be parallel in another organism. [167]
Albeit colorectal cancer is governed by the general mechanisms described above, the existence
of a different mutational spectrum between patients with the same type of cancer has been
broadly reported. [168] The experimental confirmation of the ‘just right hypothesis’ [169]
provided new insights into the importance of the genetic background of the patient in
determining tumourigenesis and tumor progression.
Even the triggered mechanisms into the tumor cells contribute to such divergence: Bielas et al.
determined the mutational rate in tumors and found that was, on average, 200 times greater
than in normal cells. This finding uncovered a novel cancer mechanism called point mutation
instability (PIN) [170, 171], and can have consequences over pharmacogenomic assays.
4.4. Intratumor heterogeneity
As stated before [116], intratumor heterogeneity may explain the difficulties encountered in
the validation of oncology biomarkers owing to sampling bias. As consequence of the different
conditions that tumor cells undergone, tumor cells have to adjust their behavior. The adapta‐
tion process to these variable circumstances is accompanied by a differential mutational
process that results in a genetic heterogeneous blend of cells.
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Gerlinger et al [172] demonstrated performing exome sequencing in primary renal carcinomas
that 63 to 69% of all somatic mutations were not detectable in all the samples from different
tumor sections. They also found biomarkers of good and poor prognosis in the analysis of
different regions of the same tumor and high intratumor heterogeneity when ploidy was
measured. [172] These findings indicate that intratumor heterogeneity is one of the most
important obstacles in the establishment of biomarkers of both prognosis and response to
treatment, what implies that the approaches that, so far, have been realized have to change.
4.5. Stem cells
Other possible pitfall can be the contribution of cancer stem cells to drug resistance. As
explained before, identification of the appropriate cell to direct therapy is essential to eradicate
cancer. Even though treatments can decrease tumor burden, if drugs do not target the
appropriate cell, chemotherapy can, as much, become a disease in chronic but not eliminate it
from the organism, as it has proved in leukemias. Stem cells are the only tumor-initiating cells
within a malignancy and therefore have been shown to maintain colorectal cells population,
[173] in fact, they account for about 2.5%% of cancer cells in CRC. [13] But the current chemo‐
therapy is not specific for these cells, and possibly cancer stem cells are naturally resistant to
chemotherapy through quiescence, capacity for DNA repair or expression of genes affecting
transport and effective drug release into the cells as ABC-transporter. [174]
Even more, stem cells itself are related to genetic background of the tumor. Mutations in APC
gene can increase the number of stem cells via Wnt signaling, promoting tumorigenesis [169].
4.6. Response to chemotherapy
Introduction of chemotherapy is a determinant selection factor of cell survival. The appearance
of resistance cells to treatments due to mutations that prevent treatment efficiency either by
selection of pre-existent resistant clones, either by the emergence of mutants clones induced
by the drug, either by inducing the segregation of protective molecules by autocrine or
paracrine mechanism or molecules that bypass the activity of the drug, adds new difficulties
to both, discovery of clear biomarkers and development of drugs that cure cancer.
4.7. Difficulty of identification or characterization of specific histologic subtypes
Histological identification of different colorectal cancer subtypes can be tough due to its
heterogeneity which makes it hardly dependent on the pathologist to identify the polyp. [37]
This fact introduces an error in the genotype-phenotype correlations that obscures biomarkers
identification.
4.8. Techniques limitations
The existence of high intratumor heterogeneity reveals the scarcity in the information that can
be obtained from a tumor and the impossibility, so far, of study bigger regions of the tumor
either because of the limited laboratory resources and high cost disclose high intratumor
heterogeneity is a difficult obstacle to overcome.
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Detection of genetic abnormalities is subject to the proper target identification and design of
the methodologies used. For example, one of the difficulties to categorized CIMP is the choice
of the appropriate panel of loci to study methylation. [175, 176]
4.9. Studies design
The classification of the groups is often different among studies. To analyse the statistical
association of a biomarker, some studies group patients in I-II stage and III-IV of cancer, having
each group a different association [positive, negative or not association with respect to the
analysed trait] meanwhile others does that with II-III stages. The different criteria used to
group patients, is obviously a source of contradictions, since studies compare results obtained
from patients with different characteristics. The different methodologies used between studies
is another source of confuse. [62, 83]
Some limitations in studies design are an obviously consequence of the resources restraints,
either economic or by shortage of the sample but extrapolation of results from these studies
are more hazardous.
The reality of high tumor heterogeneity and dynamic change of tumor behaviour makes easy
to understand the very little information we can acquire when study only one, two or three
markers in one slice of the tumor and this is even worse when study not targeted drugs since
cell have more options to overcome their effect like compensatory mechanisms.
As Greaves and Maley expose °genome profiles under-estimate complexity° and continue ° It
may be that only a modest number of phenotypic traits are required to negotiate all constraints
and evolve to full malignant or metastatic status but the inference is that this can be achieved
by an almost infinite variety of evolutionary trajectories and with multiple, different combi‐
nations of driver mutations° [7]
The limited capacity to detect low- prevalence clones are another source of a possible future
selection of resistance. [7]
Another reason for inconsistencies is small study sample sizes. Typically biomarker studies
are done in a subset of patients enrolled in a main study and, therefore, often not statistically
adequate to answer clinical questions. Analysis is hampered further by multiple comparisons
in correlative studies. Although this approach is crucial to sound statistical methodology,
correction for multiple comparisons [or the failure to do so] has probably led to heterogeneity.
A major statistical flaw is the potential for false-positive associations because of assessment of
multiple SNPs. The opposite is a concern too; biologically important associations frequently
cannot be detected after stringent correction because the selection of SNPs is too broad. Study
power might also be inadequate if SNPs with excessively rare minor allele frequency are
selected. Finally, racial heterogeneity within the trial is important to take into account, and
proper correction or analysis of patients in subgroups by ethnic origin must be done.
Due to the need of major research projects, both in number of samples as in appropriate
resources for their study, consolidate research consortia has become imperative.
The establishment of clear genotype-phenotypes correlations is still a wide and difficult field
of study due to the previously exposed heterogeneity and overlapping characteristics observed
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in colorectal cancer in both histological and molecular level, exacerbated by the confusion in
identifying some histologic subtypes of polyps and the designing problem of the studies,
which often compare only a few markers and patients in different stages, and with different
treatments, that as previously show have an impact in the molecular mechanism trigger. As
consequence, some of the published associations are not lately replicated
5. Conclusion
The clinical application of pharmacogenetic tests is still limited to a few drugs. But, the fact
that a significant number of patients obtain no advantage receiving chemotherapy encourage
us to increase the efforts to get more and better biomarkers. Knowledge of the problems
outlined above gives us a better understanding of the challenges of pharmacogenetics and
allow us to reach a better understanding of the biological basis of cancer treatments. While
that work continues, new genomic technologies now in development are enabling to bring
useful biomarkers from the bench to bedside in a more rapid and effective way.
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